Key result
CMR is linked to a ~151% higher diagnostic rate for definite cardiomyopathies versus initial clinical diagnosis.
Why the study?
To evaluate the diagnostic rate of several common myocardial diseases and explore the re-diagnostic value of CMR in clinical management.
Does cardiac magnetic resonance improve the diagnostic rate compared to initial clinical evaluation in patients with suspected cardiomyopathies?
Observational (n=954)
No
Does cardiac magnetic resonance improve the diagnostic rate compared to initial clinical evaluation in patients with suspected cardiomyopathies?
Cardiac magnetic resonance provides significant incremental diagnostic value over standard clinical evaluation for various cardiomyopathies, particularly arrhythmogenic cardiomyopathy, cardiac amyloidosis, and hypertrophic cardiomyopathy mimics.
Answers are grounded in this paper and cite their sources.
Supports incremental diagnostic value of CMR in suspected cardiomyopathies; leaves open effects on management and outcomes.
The specific advantages of cardiac magnetic resonance (CMR) for the diagnosis and treatment of several cardiovascular diseases, in terms of diagnostic accuracy,[1,2] patient outcomes,[3,4] and cost-effectiveness, have been highlighted.[5] CMR is a multi-sequential and multi-parametric imaging modality used for morphological, functional, and histological characterization, which plays an important role in the diagnosis, including differential diagnosis, of cardiomyopathies. The objectives of this study were to analyze the diagnostic rate of several common myocardial diseases through a random sampling survey, and to explore the re-diagnostic value of CMR in the clinical management of common cardiovascular diseases. Consecutive patients who had been recommended to undergo CMR and were diagnosed with definite cardiovascular diseases at final diagnosis were enrolled in this retrospective observational study. This study was approved by the ethics committee of Fuwai Hospital (2021-1590, March 4, 2022). The main focus of the study was statistical analysis of re-diagnostic rates of myocarditis, cardiac amyloidosis, left ventricular non-compaction cardiomyopathy (LVNC), apical hypertrophic cardiomyopathy (ApHCM), arrhythmogenic cardiomyopathy (ACM), and hypertrophic cardiomyopathy (HCM) mimics, including Fabry and Danon diseases. Patients finally diagnosed with myocarditis, ACM, cardiac amyloidosis, and ApHCM were included from January 5, 2021 to May 14, 2023. Given the low incidence rates of LVNC and HCM mimics, the time span for patient inclusion was extended to July 17, 2009–April 11, 2023. The re-diagnostic rate was defined as the percentage of patients in the total patient group who received a “new diagnosis” through CMR[3]; for patients who received a “new diagnosis”, the initial comprehensive clinical evaluation and examination did not result in a definitive diagnosis.[1,6] The initial diagnosis was defined as the pre-CMR diagnosis made by clinicians at admission, based on clinical symptoms and the results of electrocardiograph, Holter, echocardiography, and laboratory tests. The CMR diagnosis was made by experienced cardiovascular radiologists. Final diagnosis was made by clinicians, based on magnetic resonance images, endomyocardial biopsies, and genetic tests. Diagnosis of ApHCM mainly depended on CMR, while the final diagnosis of acute myocarditis and ACM primarily relied on hospitalization evaluation combined with CMR examination, as well as pathological examination results for a proportion of patients. Cardiac amyloidosis diagnosis was mainly based on pathological biopsy, while diagnosis of HCM mimics used genetic testing data combined with pathological biopsy. The McNemar test was used to compare the diagnostic rate between initial diagnosis and CMR diagnosis. All statistical analyses were conducted using SPSS Statistics (version 24.0, IBM, New York, USA). Patients (n = 954) finally diagnosed with various types of cardiomyopathy, including 182, 169, 41, 200, and 331 with myocarditis, cardiac amyloidosis, LVNC, ApHCM, and ACM, respectively, and 31 patients with HCM mimics (15 with Fabry disease and 16 with Danon disease) were recruited to this study. Significantly fewer patients were diagnosed with definite cardiomyopathies at initial clinical diagnosis (36.7% (350/954)) than were diagnosed by radiologists through CMR examination (92.1% (879/954); P < 0.001) [Supplementary Table 1, https://links.lww.com/CD9/A69]. In addition, CMR diagnostic rates were higher to initial diagnostic rates for ACM, cardiac amyloidosis, LVNC, myocarditis, ApHCM, and HCM mimics, and the differences were obviously significant (all P < 0.001). The CMR re-diagnosis rate for all included patients was 55.5% (529/954), among which ACM (68.3% (226/331)), cardiac amyloidosis (63.3% (107/169)), and HCM mimics (61.3% (19/31)) had relatively higher re-diagnostic rates [Figure 1], while those for LVNC, ApHCM, and myocarditis were 58.5% (24/41), 43.0% (86/200), and 36.8% (67/182), respectively.Figure 1: Diagnostic rates of various types of cardiomyopathy. Colored bars, diagnostic rates of cardiomyopathies by CMR. Colored bars with diagonal lines, initial clinical diagnostic rates of cardiomyopathies. Colored bars without diagonal lines, re-diagnostic rates of CMR of cardiomyopathies. White bars with dotted boxes, rates of patients who had negative initial and CMR diagnoses but received a positive final diagnosis. ACM: Arrhythmogenic cardiomyopathy; ApHCM: Apical hypertrophic cardiomyopathy; CA: Cardiac amyloidosis; CMR: Cardiac magnetic resonance; HCM: Hypertrophic cardiomyopathy; LVNC: Left ventricular non-compaction cardiomyopathy.Our data demonstrate that the advantages of CMR, in providing quantitative assessment of cardiac morphological, functional and histological characteristics in a single imaging examination [Figure 2], are valuable for re-diagnosis of various myocardial diseases, particularly ACM, cardiac amyloidosis, and HCM mimics. CMR has become the gold standard for assessing cardiac morphology and function. Moreover, based on its exceptional value for imaging mimicking-pathology, this so-called pathological imaging is of great importance for the differential diagnosis and risk stratification of cardiomyopathies.[7]Figure 2: Cardiac magnetic resonance images showing short-axis view of various cardiovascular diseases: The top row, LGE; the middle row, native T1; and the bottom row, ECV. Examples of (A) LGE in the right ventricular free wall and septum in ACM; (B) Dust-like LGE in left ventricular inferior lateral wall in CA, as well as the high native T1 value and ECV value; (C) Abnormal chordae tendineae from the anterior septum to the anterior wall of the left ventricle in LVNC; (D) Linear subepicardial LGE in the inferior lateral wall of the left ventricle in myocarditis, as well as relatively high myocardial native T1 value and ECV value in the corresponding region; (E) Significant thickening of the left ventricular apex in ApHCM; (F) Faint hazy LGE within the myocardial wall in Fabry disease, as well as relatively low native T1 value and normal ECV value; (G) Diffuse multiple LGE in the septum, left ventricular free wall, and right ventricular wall in Danon disease, as well as relatively high myocardial native T1 value and ECV value. ACM: Arrhythmogenic cardiomyopathy; ApHCM: Apical hypertrophic cardiomyopathy; CA: Cardiac amyloidosis; ECV: Extra-cellular volume; LGE: Late gadolinium enhancement; LVNC: Left ventricular non-compaction cardiomyopathy.ACM (including right ventricular, biventricular, and left-dominant forms) is a myocardial disease characterized by the substitution of myocardium by fibrous or fibrofatty scar tissue.[8] The ability to conduct detailed left ventricular and right ventricular morpho-functional and tissue characterization using CMR has led to emergence of this type of imaging as the technique of choice for ACM evaluation. For example, cine CMR can be used to detect early typical characteristics of ACM, such as focal right ventricular akinesia, dyskinesia, microaneurysms, the accordion sign, and the butterfly apex, among others.[9] In addition, the late gadolinium enhancement technique enables visualization of hallmark lesions, including fibrous and fibrofatty myocardium replacement. Late gadolinium enhancement is also helpful to categorize phenotypic variants of ACM, and helps in risk stratification of patients with arrhythmic events.[10,11] In addition to the clinically mature late gadolinium enhancement imaging approach, parametric quantitative imaging also has considerable advantages. For example, cardiac amyloidosis is characterized by amyloid fibril deposition within the myocardial extra-cellular space, which leads to myocardium pseudohypertrophy. T1 and extra-cellular volume maps can be used to quantify myocardial amyloid burden in the early stage of cardiac amyloidosis, before it is detectable by late gadolinium enhancement.[12] Thus, high T1 and extra-cellular volume values are crucial to cardiac amyloidosis diagnosis. In addition to cardiac amyloidosis, many other cardiovascular diseases also lead to myocardial hypertrophy; even the hearts of healthy people and athletes show ventricular wall thickening. In addition to distinguishing physiological from pathological hypertrophy, it is important to identify the causes of the various HCM mimics (Fabry disease, Danon disease, etc), as this fundamentally impacts the formulation of treatment strategies and prognosis evaluation. For example, Fabry disease features intracellular lipid accumulation with fat vacuoles, while the extra-cellular space is not significantly affected and can be diagnosed by CMR with low native T1 value and normal extra-cellular volume value.[13] Thompson et al[14] found that T1 mapping exhibits sensitivity and specificity for identification of patients with Fabry disease, independent of sex, and left ventricular shape and function. Pica et al[15] also observed the role of native T1 as an early marker of Fabry disease, detecting decreased native T1 values preceding left ventricular hypertrophy in 40% of cases. In summary, quantitative assessment of cardiac morphological, functional, and histological characteristics by CMR contributes to relatively high re-diagnosis rates in patients with ACM, cardiac amyloidosis, and HCM mimics. Routine use of CMR should be considered in centers equipped with adequate CMR facilities, taking into account its implications for the management of patients with new diagnosis by CMR. Importantly, diagnosis by CMR enables initiation of effective prevention treatment. Furthermore, CMR facilitates more reliable longitudinal comparisons of measurements in the same subject, starting from the early stages of the disease, which is particularly important for developing management strategies and conducting prognosis evaluation. Therefore, the re-diagnostic ability of CMR may also be important in prognosis evaluation and risk stratification for patients with cardiovascular diseases, and further exploration in future research is warranted. Similarly, CMR has an essential role in the re-diagnosis of other cardiovascular diseases. CMR was reported as identifying previously unknown diagnoses in 27% of patients who experienced heart failure with preserved ejection fraction[3]; this cohort of additional diagnoses correlated with worse outcomes and served as an independent prognostic factor for mortality and hospitalization due to heart failure. In addition, Aquaro et al[16] investigated the diagnostic implications of CMR for differential diagnosis of left ventricular hypertrophy, and found that CMR changed diagnosis of the type of left ventricular hypertrophy in 42% of patients, which was associated with a substantial variation in the risk of patient cardiac events. The diagnostic rate of HCM increased from 44% in the initial echocardiographic diagnosis to 71% in CMR diagnosis. The re-diagnostic rate of HCM in the study by Aquaro et al[16] was lower than that for ApHCM in our study, which may be due to the multiple types of HCM included in the study by Aquaro et al[16], further emphasizing the unique re-diagnostic value of CMR for ApHCM. The high re-diagnosis rates of CMR for these various types of cardiovascular disease clearly demonstrate its irreplaceable clinical value for final diagnosis and prognosis evaluation. CMR is both the gold standard for quantitative evaluation of cardiac structure and function and able to accurately identify myocardial histological characteristics, such as myocardial edema, fibrosis, and fatty infiltration, in vivo. Compared with clinical symptoms, electrocardiogram examination, and laboratory tests, CMR can provide considerable added value for disease diagnosis. In addition, due to variability in geometric assumptions, patient factors, and operator inconsistencies, echocardiography has limited reproducibility and is particularly susceptible to apical/near field errors. Consequently, it may sometimes fail to accurately diagnose conditions such as HCM and amyloidosis.[6,17] Together, these factors may contribute to discrepancies observed between initial and CMR diagnoses. Our study had some limitations. First, our reliance on retrospective data and a single-center study design limits the generalizability of the results. A larger sample size and a multi-center study to investigate the re-diagnostic value of CMR would be preferable. Additionally, CMR has inherent limitations, such as high cost, limited accessibility, and contraindications in some patients, which can lead to practical challenges in increasing the use of CMR in clinical practice. In conclusion, compared with clinical and echocardiographic examination, CMR is highly valuable for final diagnosis and should be strongly recommended for early diagnosis and clinical management of patients with various myocardial diseases. In this study, more than half of the initial diagnoses were modified by CMR, informing decisions on subsequent precision treatments and optimizing medical resource use. We call on medical insurance departments, medical institutions, and cardiologists to pay attention to the re-diagnostic value of CMR.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2025) conducted an observational in Cardiomyopathies (n=954). Cardiac magnetic resonance (CMR) vs. Initial clinical diagnosis was evaluated on Diagnostic rate of definite cardiomyopathies (p=<0.001). Cardiac magnetic resonance improved the diagnostic rate of definite cardiomyopathies compared to initial clinical diagnosis.
Synapse has enriched 10 related papers. Consider them for comparative context: